Antigenic Characterization of Circulating and Emerging SARS-CoV-2 Variants in the U.S. throughout the Delta to Omicron Waves.
Di H, Pusch EA, Jones J, Kovacs NA, Hassell N, Sheth M, Lynn KS, Keller MW, Wilson MM, Keong LM, Cui D, Park SH, Chau R, Lacek KA, Liddell JD, Kirby MK, Yang G, Johnson M, Thor S, Zanders N, Feng C, Surie D, DeCuir J, Lester SN, Atherton L, Hicks H, Tamin A, Harcourt JL, Coughlin MM, Self WH, Rhoads JP, Gibbs KW, Hager DN, Shapiro NI, Exline MC, Lauring AS, Rambo-Martin B, Paden CR, Kondor RJ, Lee JS, Barnes JR, Thornburg NJ, Zhou B, Wentworth DE, Davis CT.
Di H, et al. Among authors: park sh.
Vaccines (Basel). 2024 May 7;12(5):505. doi: 10.3390/vaccines12050505.
Vaccines (Basel). 2024.
PMID: 38793756
Post fourth-dose bivalent vaccinee sera provided better protection against those subvariants, but substantial reductions in neutralization titers were still observed, especially among BA.4/5 subvariants with both an N-terminal domain (NTD) deletion and receptor binding domain (RB …
Post fourth-dose bivalent vaccinee sera provided better protection against those subvariants, but substantial reductions in neutralization t …